Kamada Ltd. is an Israeli biopharmaceutical company focused on the development, manufacturing, and commercialization of specialty plasma-derived protein therapeutics for rare and serious conditions. The company's business model centers on its proprietary platform technology for extracting and purifying proteins from human plasma. Kamada's commercial portfolio includes six FDA-approved products, notably GLASSIA, the first liquid, ready-to-use intravenous AAT product for treating Alpha-1 Antitrypsin deficiency, and KEDRAB, an anti-rabies immune globulin. Other key products include CYTOGAM, HEPAGAM B, VARIZIG, and WINRHO SDF, which were acquired to expand its U.S. commercial footprint in the hyper-immune market. Revenue is primarily generated through product sales and strategic distribution partnerships, such as its agreements with Takeda for GLASSIA and Kedrion for KEDRAB. Geographically, Kamada has a strong presence in the United States, which accounts for a significant portion of its sales, while also distributing products in over 30 international markets. The company maintains a competitive position in the orphan drug and specialty plasma market by leveraging its specialized manufacturing capabilities at its Beit Kama facility and expanding its proprietary plasma collection network.
